Alkermes plc (ALKS) vs Medtronic plc (MDT)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ALKS | MDT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Medical Devices |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | NYSE |
| Country | Ireland | Ireland |
| Theme | neuroscience | medical-devices |
| Price and returns | ||
| Last close | $44.44 | $94.79 |
| Return · 1 week | +3.42% | +2.18% |
| Return · 1 month | +10.68% | +5.91% |
| Return · 3 months | −12.00% | +9.10% |
| Return · year to date | +57.25% | −0.51% |
| Return · 1 year | +49.53% | +2.27% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −20.17% | −10.85% |
| 52-week high | $55.67 | $106.33 |
| 52-week low | $27.00 | $73.31 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $7.46B | $121.25B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $69.27M | $935.77M |
| Employees | 2,050 | 95,000 |
| Valuation | ||
| Price to earnings · trailing | 108.47× | 22.40× |
| Price to earnings · forward | 22.80× | 14.21× |
| Price to sales | 4.15× | 3.10× |
| Price to book | 3.82× | 2.32× |
| Enterprise value to EBITDA | 27.48× | 13.10× |
| Enterprise value to revenue | 4.70× | 3.63× |
| PEG ratio | 1.96 | 1.65 |
| Earnings per share · trailing | 0.38 | 4.06 |
| Profitability | ||
| Gross margin | 84.56% | 65.01% |
| Operating margin | 15.50% | 19.33% |
| Profit margin | 3.97% | 13.93% |
| Return on equity | 3.85% | 10.65% |
| Return on assets | 4.20% | 5.12% |
| Growth | ||
| Revenue growth | +27.00% | +13.70% |
| Earnings growth | −99.40% | +40.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | 86.95 | 55.37 |
| Current ratio | 2.30 | 2.07 |
| Dividend yield | 0.00% | 3.17% |
| Payout ratio | 0.00% | 70.20% |
| Trend and volatility | ||
| RSI · 14 | 57.78 | 57.85 |
| ADX · 14 | 25.58 | 21.71 |
| 50-day average | $44.40 | $91.44 |
| 200-day average | $40.17 | $88.20 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.31% | 2.72% |
The full ALKS analysis
Everything this table leaves out for Alkermes plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ALKS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ALKS analysisThe full MDT analysis
Everything this table leaves out for Medtronic plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MDT argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MDT analysis